Display options
Cite
Emamgholipour S, Moradi N, Beigy M, et al. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr. 2015;7:108doi: 10.1186/s13098-015-0099-z.
Emamgholipour, S., Moradi, N., Beigy, M., Shabani, P., Fadaei, R., Poustchi, H., & Doosti, M. (2015). The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetology & metabolic syndrome, 7108. https://doi.org/10.1186/s13098-015-0099-z
Emamgholipour, Solaleh, et al. "The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study." Diabetology & metabolic syndrome vol. 7 (2015): 108. doi: https://doi.org/10.1186/s13098-015-0099-z
Emamgholipour S, Moradi N, Beigy M, Shabani P, Fadaei R, Poustchi H, Doosti M. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr. 2015 Nov 25;7:108. doi: 10.1186/s13098-015-0099-z. eCollection 2015. PMID: 26613006; PMCID: PMC4660841.
Copy Download .nbib Format: NLM
Share it on

Diabetol Metab Syndr. 2015 Nov 25;7:108. doi: 10.1186/s13098-015-0099-z. eCollection 2015.

The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study.

Diabetology & metabolic syndrome

Solaleh Emamgholipour, Nariman Moradi, Maani Beigy, Parisa Shabani, Reza Fadaei, Hossein Poustchi, Mahmood Doosti

Affiliations

  1. Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  2. Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  3. Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  4. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 26613006 PMCID: PMC4660841 DOI: 10.1186/s13098-015-0099-z

Abstract

BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters.

METHODS: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay.

RESULTS: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = -0.337; p = 0.002), fasting blood glucose (FBG) (r = -0.488; p < 0.001), triglyceride (TG) (r = -0.245; p = 0.031), HOMA-IR (r = -0.492; p < 0.001), insulin(r = -0.338; p = 0.002), LS (r = -0.544; p < 0.001), alanine aminotransferase (ALT) (r = -0.251; p = 0.027), waist-to-hip ratio (WHR) (r = -0.352; p = 0.002) and waist circumference (WC) (r = -0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM.

CONCLUSIONS: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD.

Keywords: CTRP5; Insulin resistance; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus

References

  1. PLoS One. 2014 May 14;9(5):e94478 - PubMed
  2. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3363-71 - PubMed
  3. Diabetes Care. 2013 Oct;36(10):3321-7 - PubMed
  4. PLoS One. 2014 Jun 26;9(6):e99785 - PubMed
  5. J Clin Invest. 2000 Aug;106(4):473-81 - PubMed
  6. Hepatology. 2010 Feb;51(2):679-89 - PubMed
  7. Clin Exp Med. 2014 May;14(2):121-31 - PubMed
  8. Hepat Mon. 2011 Feb;11(2):103-6 - PubMed
  9. Trends Immunol. 2007 Sep;28(9):393-9 - PubMed
  10. Diabetol Metab Syndr. 2015 Apr 10;7:33 - PubMed
  11. Diabetes Metab. 2013 Feb;39(1):16-26 - PubMed
  12. Gastroenterology. 2012 Apr;142(4):711-725.e6 - PubMed
  13. FEBS Lett. 2010 Jul 16;584(14):3080-4 - PubMed
  14. Rev Endocr Metab Disord. 2014 Jun;15(2):111-23 - PubMed
  15. Biochem J. 2008 Dec 1;416(2):161-77 - PubMed
  16. Clin Liver Dis. 2015 May;19(2):361-79 - PubMed
  17. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5505-13 - PubMed
  18. Clin Sci (Lond). 2004 Jun;106(6):635-43 - PubMed
  19. J Biol Chem. 2009 Oct 9;284(41):27780-9 - PubMed
  20. J Med Genet. 2008 Jan;45(1):22-8 - PubMed
  21. Clin Sci (Lond). 2009 Apr;116(7):539-64 - PubMed
  22. Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1096-105 - PubMed
  23. Hepatology. 2010 May;51(5):1820-32 - PubMed
  24. Am J Physiol Gastrointest Liver Physiol. 2013 Aug 1;305(3):G214-24 - PubMed
  25. Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21 - PubMed
  26. Curr Opin Lipidol. 2006 Jun;17(3):268-73 - PubMed
  27. Clin Exp Med. 2016 May;16(2):193-202 - PubMed
  28. Curr Mol Med. 2009 Apr;9(3):299-314 - PubMed
  29. Trends Endocrinol Metab. 2012 Apr;23(4):194-204 - PubMed
  30. J Gastroenterol. 2013 Apr;48(4):434-41 - PubMed
  31. J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504 - PubMed
  32. Exp Clin Endocrinol Diabetes. 2013 May;121(5):310-7 - PubMed
  33. Trends Endocrinol Metab. 2008 Dec;19(10):371-9 - PubMed
  34. Diabetol Metab Syndr. 2014 Oct 14;6:109 - PubMed
  35. Diabetes Care. 2012 Jan;35 Suppl 1:S64-71 - PubMed
  36. J Biol Chem. 2012 Jan 6;287(2):1576-87 - PubMed
  37. Clin Biochem. 2013 Jan;46(1-2):73-8 - PubMed
  38. Pathophysiology. 2008 Aug;15(2):91-101 - PubMed
  39. J Viral Hepat. 2007 May;14(5):360-9 - PubMed
  40. Liver Int. 2006 Dec;26(10):1209-16 - PubMed
  41. J Clin Invest. 1996 Jun 15;97(12):2859-65 - PubMed
  42. Diabetes. 2012 Nov;61(11):2932-6 - PubMed
  43. PLoS One. 2015 Mar 13;10(3):e0118650 - PubMed
  44. Biochem Biophys Res Commun. 2014 Sep 26;452(3):715-21 - PubMed
  45. Lipids Health Dis. 2012 Feb 23;11:30 - PubMed
  46. Am J Physiol Regul Integr Comp Physiol. 2013 Sep;305(5):R522-33 - PubMed

Publication Types